Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Open-Label Safety Study of Aducanumab in Previously Enrolled Alzheimer's Disease Participants
2019-004368-22Phase 3Completed
- Sponsor
- Biogen
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aducanumab in Alzheimer's disease (AD), sponsored by Biogen. Primary endpoint: Safety and tolerability over 100 weeks of aducanumab treatment. Started Mar 2020; status: completed.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2019-004368-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004368-22.